Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has announced positive results from its Phase III study of Benmelstobart Injection combined with chemotherapy, followed by Anlotinib Hydrochloride Capsules as a first-line treatment for advanced squamous non-small cell lung cancer. The interim analysis showed significant improvement in progression-free survival compared to the existing treatment, marking a promising development for patients with this challenging cancer subtype. The company plans to submit a marketing application for this new indication soon, which could offer new hope for cancer treatment.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
